Project Development

Kristina Rhoades

Email: abpl0j@r.postjobfree.com

Address: *** ******* **.

City: Crowley

State: TX

Zip: 76036

Country: USA

Phone: 817-***-****

Skill Level: Management

Salary Range: $100,000

Willing to Relocate

Primary Skills/Experience:

See Resume

Educational Background:

See Resume

Job History / Details:

NOVARTIS INSTITUE FOR BIOMEDICAL RESEARCH

6201 SOUTH FREEWAYaa FORT WORTH, TX 76134 aa TEL. 817-***-****

FAX 817-916-9241aa E-MAIL: abpl0j@r.postjobfree.com

800 BUFFALO CT. aa CROWLEY, TX 76036 aa TEL. 817-***-****

KRISTINA L. RHOADES, Ph.D.

SUMMARY

I am a research scientist with a Ph.D. from UCLA in microbiology and immunology and postdoctoral training from Harvard Medical School and the Whitehead Institute at MIT. After transitioning to pharmaceutical research, I have had experience as a research scientist, project leader and assistant director of therapeutic drug discovery research.

OBJECTIVE

To utilize my skills and knowledge of pharmaceutical drug discovery research and management to support drug development.

SPECIFIC SKILLS

aa 10 years of management experience in drug discovery research

aa An in depth understanding of discovery research, pharmacodynamics, pharmacokinetics and safety research

aa Excellent communication and organizational skills

aa An ability to aaAget the job doneaa regardless of the task

PRESENT POSITION

Associate Director, Cellular and Molecular Retinopathy, Novartis Research January, 2012-present

Assistant Director, Cellular and Molecular Retinopathy, Alcon Research July, 2007-Dec., 2011

Principle Scientist, Retina Research, Degenerative Diseases, Alcon Research Sept., 2004-July, 2007

Accomplishments:

aa Established relevant assays for the identification and evaluation of potential therapeutics for protection of neurons and other retinal cell types from insults implicated in the progressive degeneration observed in geographic atrophy and AMD.

aa Direct efforts have provided in vitro analysis of potential therapeutics for AMD and provided support for in vivo evaluation in relevant animal models.

aa Established mechanism of action for a lead compound now in clinical development.

aa Worked directly with the Development to provide research support for the development of a lead compound, including mechanistic studies, determination of IC50 in a variety of species, and the effect of various dosing paradigms.

aa Directed the in vitro research efforts of a diverse group of scientists in the development and utilization of assays addressing aspects of neovascularization, oxidative damage and the role of complement activation in AMD.

aa Established and managed outside collaborations with academic and industrial organizations.

PREVIOUS POSITIONS

Associate Director, Neurodegenerative Disease/Ophthalmology, Immusol, Inc. July, 2003-Sept. 2004

Senior Project Leader, Neurodegenerative Diseases, Immusol, Inc. Jan. 2003-June, 2003

Project Leader, Neurodegenerative Diseases, Immusol, Inc. 2000-Dec. 2002

Accomplishments:

aa Identification of therapeutic targets that protect neurons from apoptotic and non-classical programmed cell death.

aa High through-put target validation for neuronal survival.

aa Developed 3 screens to identify therapeutic targets to increase degradation of AI and protect neurons.

aa Developed multiple screens to identify therapeutic targets that protect RPE cells from the effects of neovascularization and vessel leakage.

aa Directed a group of up to 8 individuals with multiple projects and goals including neurodegenerative diseases, cancer apoptosis, technology development and ophthalmology.

FORMAL TRAINING

Senior Research Associate, The Scripps Research Institute, La Jolla CA 1999-2000

Projects:

aa Analysis of mice expressing AML1/ETO under control of a tet inducible system. Studies included progenitor assays, and northern, and RT-PCR expression analysis.

aa Development of cell lines expressing AML1/ETO in a tet inducible system. Studies involving analysis of differential gene expression in response to expression of AML1/ETO.

aa . Other responsibilities included directing the research of other laboratory personnel and maintenance of mouse lines

Postdoctoral Fellow, Whitehead Institute for Biomedical Research, Cambridge, MA 1996-1999

Projects:

aa Generated single cell cDNA libraries from dissociated circumvallate papillae. Isolated differentially expressed genes from taste tissue.

aa Developed novel single cell RT-PCR assay to analyze allelic expression of Pax 5 and IL-2.

aa Demonstrated that Pax 5 is biallelically expressed and that IL-2 is monoallelically expressed in a subset of CD4+ T cells and biallelically expressed in another subset of CD4+ T cells.

aa Developed a single cell RT-PCR assay to analyze expression of intronless genes to eliminate contamination due to DNA amplification.

Postdoctoral Fellow, Harvard Medical School, Beth Israel Hospital, Boston MA 1994-1996

Projects:

aa Examined transcription factor levels during hematopoiesis using semi-quantitative RT-PCR.

aa Isolated CD34+ cells from human bone marrow to study hematopoietic differentiation and the factors required for production of myeloid, erythroid and granulocytic lineages.

aa Transiently transfected myeloid cell lines to investigate the effect of AML-1/ETO expression on MCSF receptor expression and its involvement in leukemogenesis.

aa Examined the role of MCSF receptor and C/EBPI expression in leukemogenesis in response to the 8:21 translocation using semi-quantitative RT-PCR and northern analysis of patient bone marrow samples.

aa Constructed, produced and tested AAV vectors for use in gene therapy of CD34+ stem cells.

EDUCATION

Ph.D. in Microbiology and Immunology, University of California, Los Angeles 1989-1994

Thesis Projects:

aa Constructed reporter constructs with the TNFI promoter and used them in transient transfection assays in B cell, T cell and myeloid cell lines.

aa Performed deletion analysis and site directed mutagenesis of the TNFI promoter to identify elements involved in phorbol ester and cytokine regulation of TNFI gene expression.

aa Used DNA footprinting to correlate elements of the TNFI promoter bound by transcription factors with elements identified as important by functional promoter studies.

aa Constructed retroviral vectors expressing the neomycin resistance gene or Iaagalactosidase for use in clinical marking trials of tumor infiltrating lymphocytes.

aa Constructed and produced adenoviral vectors expressing cytokines for use in animal studies of melanoma and fibrosarcoma.

B.S. in Microbiology, University of California, Los Angeles 1986

OTHER EXPERIENCE

Staff Research Associate, University of California, Los Angeles 1986-1989

aa Studies of cytokine gene expression by activated human monocytes, in particular, TNFI and IL-1.

aa Analyzed factors involved in regulation of gene expression by the HTLV I long terminal repeats.

LEADERSHIP AND TEAMWORK EXPERIENCE

Scientific Partner for Alcon research Institute 2011

Global Leadership Development Program, Alcon Research 2009

Leader of In Vitro group for Retina Research/Degenerative Diseases 2004-Present

External representation of Immusol and the Neurodegenerative Diseases group 2001-2004

Project leader of neurodegenerative diseases group, Immusol, Inc. 2000-2004

Supervision of technical assistants and research scientists, Harvard, MIT 1996-2000

Teaching Asst. in Medical Virology with I.S.Y. Chen, UCLA 1990

HONORS AND AWARDS

National Institutes of Health, Postdoctoral fellowship 1995-1998

National Institutes of Health, Training Grant recipient 1991-1992

Associated Western Universities Scholarship 1985

PROFESSIONAL MEMBERSHIPS

ARVO

PATENTS

aa Co-inventor on patent application entitled, aaAMethods for Treating Macular Edema and Pathologic Ocular Angiogenesis Using a Neuroprotective Agent and a Receptor Tyrosine Kinase Inhibitoraa Filed July 7, 2008.

aa Co-inventor on patent application entitled, aaAMethods for Identifying Agents Useful for the Treatment of Neurodegnerative Diseases.aa Filed October 20, 2005

aa Co-inventor on patent application entitled, aaAMethods of Identifying Agents that Inhibit the Growth of Cancer Cells." Filed September 4, 2003.

aa Co-inventor on patent application entitled, aaAMethods of Inhibiting Cancer Growth by Binding to Nuclear Receptors." Filed August 5, 2003.

aa Co-inventor on patent application entitled, aaASingle Promoter System for Making siRNA Expression Cassettes and Expression Libraries Using a Polymerase Primer Hairpin Linker,aa serial number 60/399,040. Filed July 24, 2002. International publication number WO 2004/009796.

aa Co-inventor on provisional patent application entitled, aaAMethods of Identifying a Molecule that Increases Inhibition of or Resistance to Neurodegenerative Disease.aa Filed March, 2004

PUBLICATIONS

Research Articles:

Robert J. Collier, Yu Wang, Sherry S. Smith, Elizabeth Martin, Richard Ornberg, Kristina Rhoades, and Carmelo Romano. Complement Deposition and Microglial Activation in the Outer Retina in Light-Induced Retinopathy: Inhibition by a 5-HT1A agonist. Invest. Ophthalmol. Vis. Sci. published 5 April 2011, 10.1167/iovs.10-6418

Kayikcioglu OR, Cheng L, Kozak I, Bergeron-Lynn G, Schulteis CT, Rhoades KL, Freeman WR. Toxicity of subretinal ribozyme to the proliferating cell nuclear antigen and 5-fluorouracil in rat eyes.

Curr Eye Res. May;31(5):435-40. 2006.

Yang JP, Fan W, Rogers C, Chatterton JE, Bliesath J, Liu G, Ke N, Wang CY, Rhoades K, Wong-Staal F, Li QX. A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: Identifying the receptors involved in amyloid beta degradation. Genomics. Sep; 88(3): 282-92. 2006.

Rhoades, K. and Wong-Staal, F. Inverse genomics as a powerful tool to identify novel targets for the treatment of neurodegenerative diseases. Mechanisms of Ageing and Development. 124 (1); 125-32. 2003.

Rhoades, K.L., Singh, N., Simon, I., Glidden, B., Cedar, H., Chess, A. Allele-specific expression patterns of Interleukin-2 and Pax 5 revealed by a sensitive single cell RT-PCR analysis. Curr Biol. 10(13):789-92. 2000.

Rhoades, K.L., Hetherington, C.J., Harakawa, N., Yergeau, D.A., Liu, L.-Q., Little, M.-T., Tenen, D.G., and Zhang, D.-E. Analysis of the role of AML1-ETO in leukemogeneis using an inducible transgenic mouse model. Blood. 96(6):210*-**-****.

Toloza, E.M., Hunt, K., Miller, A.R., McBride, W.H., Lau, R., Swisher, S., Rhoades, K.L., Arthur, J., Choi, J., Chen, L., Chang, P., Chen, A., Glaspy, J., and Economou, J.S. Transduction of murine and human tumors using recombinant adenovirus vectors. Annals of Surgical Oncology 4: 70-79. 1997.

Rhoades, K.L., Hetherington, C.J., Tenen, D.G., Oliff, I.A., Hiebert, S.W., Nucifora, G., and Zhang, D.-E. Synergistic up-regulation of the myeloid specific M CSF receptor by AML-1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc. Natl. Acad. Sci. U.S.A . 93: 11895-900. 1996.

Rhoades, K.L., Golub, S.H., and Economou, J.S. The adenovirus transcription factor, E1A 13S, trans-activates the human tumor necrosis factor-I promoter. Virus Research 40: 65-74. 1996.

Zhang. D.-E., Hetherington, C.J., Meyers, S., Rhoades, K.L., Chen, H.M., Hiebert, S.W., Tenen, D.G. CCAAT enhancer binding protein (C/EBP) and AML1 (CBFI2) synergistically activate the M-CSF receptor promoter. Mol. Cell. Biol. 16: 1231-40. 1996.

Toloza, E.M., Hunt K., McBride, W.H., Lau, R., Pang, S., Swisher, S., Rhoades, K., Atha, T., Drake, T., Belldegrun, A., Glaspy, J., and Economou, J.S. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Therapy. 3: 11-17. 1996.

Rhoades, K.L., Cai, S., Golub, S.H., and Economou, J.S. Granulocyte-macrophage colony-stimulating factor and interleukin-4 differentially regulate the human tumor necrosis factor-I promoter region. Cell. Immunol. 161: 125-31. 1995.

Lee, J.D., Rhoades, K., and Economou, J.S. Interleukin-4 inhibits the expression of tumor necrosis factors alpha and beta, interleukins-1I and -6 and interferon-I. Immunol. Cell. Biol. 73: 57-61. 1995.

Miller, A.R., McBride, W.H., Dubinett, S.M., Graeme, J., Dougherty, J., Thacker, D., Shau, H., Kohn, D.B., Moen, R.C., Walker, M.J., Chiu, R., Schuck, B.L., Rosenblatt, J.A., Huang, M., Dhanani, S., Rhoades, K., and Economou, J.S. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: Comparison of immunological properties with IL-2. Blood, 82: 3686-94. 1993.

Miller, A.R., Skotzko, M., Rhoades, K., Belldegrun, A.S., Tso, C.-L., Kaboo, R., McBride, W.H., Moen, R., and Economou, J.S. Simultaneous use of two retroviral vectors in human gene therapy marking trials: Feasibility and potential applications. Human Gene Therapy, 3: 619-24. 1992.

Rhoades, K. L., Golub, S.H., and Economou, J.S. The regulation of human tumor necrosis factor I promoter region in macrophage, B cell and T cell lines. J. Biol. Chem., 267: 22102-107. 1992.

Miller, A.R., Skotzko, M.S., Tso, C.-L., Kaboo, R., Belldegrun, A.S., Chandler, C.F., Rhoades, K., Kohn, D., and Economou, J.S. Retroviral-mediated gene transfer into human tumor-infiltrating lymphocytes. Surgical Forum, 43: 472-75. 1992.

Lee, J.D., Sievers, T.M., Chandler, C.F., Rhoades, K., Morton, D.L., McBride, W.H., and Economou, J.S. Human melanoma cell lines produce interleukin-6. Lymph. and Cyto. Res.: 11: 161-66. 1992.

Chandler, C.F., Skotzko, M., Lee, J.D., Rhoades, K., Tso, C.-L., Belldegrun, A., McBride, W.H., Kohn, D., Golub, S.H., Holmes, E.C., and Economou, J.S. Retroviral-mediated gene transfer of interleukin-6 and interleukin-7 into human tumor-infiltrating lymphocytes. Surgical Forum 42: 470-72. 1991.

Essner, R., Rhoades, K., McBride W.H., Morton, D.L., and Economou, J.S. Differential effects of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor on tumor necrosis factor and interleukin-1 production in human monocytes. J. Clin. Lab. Immunol., 32: 161-66. 1990.

Economou, J.S., Essner, R., Rhoades, K., Yamada, T., Swisher, S.G., Holmes, E.C., Golub, S., and Morton, D.L. Genetic analysis of tumor necrosis factor promoter function in human tumor-infiltrating lymphocytes and other cell lines. Surgical Forum, 40: 448-52. 1989.

Economou, J.S., Rhoades, K., Essner, R., McBride, W.H., Gasson, J.C., and Morton, D.L. Genetic analysis of the human tumor necrosis factor I/cachectin promoter region in a macrophage cell line. J. Exp. Med., 170: 321-26. 1989.

Essner, R., Rhoades, K., McBride, W.H., Morton, D.L., and Economou, J.S. IL 4 down regulates IL-1 and TNF gene expression in human monocytes. J. Immunol. 142: 3857-61. 1989.

Economou, J. S., McBride, W.H., Essner, R., Rhoades, K.L., Golub, S., Holmes, E.C., and Morton, D.L. Tumor necrosis factor production by interleukin-2 activated macrophages in vitro and in vivo. Immunology, 67: 514-19. 1989.

Economou, J.S., Essner, R., Rhoades, K., McBride, W.H., Golub, S., Holmes, E.C., and Morton, D.L. Molecular mechanisms of interleukin-2 (IL-2) induction of human tumor necrosis factor (TNF) gene expression in macrophages. Surgical Forum, 39: 426-28. 1988.

Contact this candidate